Markets:

Overview

News

Currencies

International

Treasuries

iShares Biotechnology ETF (NQ:IBB)

165.51 -0.72 (-0.43%)

Official Closing Price Updated: 4:15 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about iShares Biotechnology ETF

< Previous 1 2 3 4 5 6 7 8 9

...

28 29 Next >

QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure ↗

March 10, 2026

H.C. Wainwright stated that the reported departure of a key U.S. Food and Drug Administration official at the end of April bodes well for uniQure.

Via Stocktwits

Topics Initial Public Offering

QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 ↗

March 09, 2026

Wells Fargo upgraded uniQure’s stock to ‘Overweight,’ citing a bullish outlook for its gene therapy following reports that Vinay Prasad will leave the U.S. FDA next month.

Via Stocktwits

Why Did CRMD Stock Tumble Over 11% Today? ↗

March 05, 2026

The company reported mixed Q4 results with a revenue of $128.6 million and earnings per share of $0.16.

Via Stocktwits

Topics Artificial Intelligence

Why Did BTAI Stock Surge 20% In Pre-Market Today? ↗

March 05, 2026

BioXcel announced positive Phase 2 results for evaluating treatment for opioid withdrawal symptoms.

Via Stocktwits

PLRZ Stock Jumps 6% In Pre-Market – Why Is This Biotech Firm Diversifying Into Aviation Business? ↗

February 10, 2026

Via Stocktwits

Why IBRX Stock Is One Of The Biggest Pre-Market Movers Today ↗

January 16, 2026

Via Stocktwits

IBRX Stock Finds Retail Cheer After Company’s Immunotherapy For Bladder Cancer Gets Saudi FDA Approval ↗

January 14, 2026

Via Stocktwits

Why Did CDXS Stock Jump 7% Today? ↗

March 04, 2026

The company tied up with an innovator pharmaceutical company to manufacture 50 grams of small interfering RNA using a proprietary ECO Synthesis platform.

Via Stocktwits

AARD Stock Slumps 54% Pre-Market – Here’s Why Analysts Are Not ‘Comfortable’ With The Suspension Of A Key Phase 3 Trial ↗

March 02, 2026

Aardvark Therapeutics shares saw brokerage downgrades after the company paused its Phase 3 trial to treat hyperphagia in patients with Prader-Willi syndrome.

Via Stocktwits

AUPH Stock Gains On Aurinia Pharma’s Q4 Beat, But 2026 Guidance Misses Estimates ↗

February 26, 2026

Aurinia reported adjusted earnings per share of $1.53 on revenue of $77.1 million, while Wall Street analysts expected an adjusted EPS of $0.22 on revenue of $74.7 million, according to Koyfin data.

Via Stocktwits

VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership ↗

February 24, 2026

Raymond James analyst Sean McCutcheon upgraded the stock to ‘Strong Buy’ from ‘Outperform’ and lifted his price target to $19 from $12.

Via Stocktwits

Why Did NRXP Stock Surge 21% Pre-Market Today? ↗

January 14, 2026

Via Stocktwits

IBRX Garners Retail Attention On Positive Update In Immunotherapy For Lung Cancer Patients ↗

January 13, 2026

Via Stocktwits

ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 1% Pre-Market ↗

February 23, 2026

Net product revenue in the fourth quarter surged 431% to $38.3 million, above estimates of $37.8 million, according to Fiscal.ai data

Via Stocktwits

Why Did ACLX Stock Surge 80% In Pre-Market Today? ↗

February 23, 2026

Gilead Sciences announced an agreement to acquire Arcellx in a $7.8 billion deal.

Via Stocktwits

SNSE Stock Surges To 21-Month High – Everything To Know About Its Faeth Therapeutics Acquisition ↗

February 18, 2026

The company said that the acquisition adds Faeth’s lead investigational therapy, PIKTOR, to its oncology portfolio.

Via Stocktwits

CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial ↗

February 17, 2026

COMPASS Pathways is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

Via Stocktwits

Vanda’s FDA Moment: A High-Stakes Bet That Could Redefine The Stock ↗

December 29, 2025

Via Stocktwits

CMPS Stock Jumps 22% Pre-Market As Compass Sets Timeline For New Phase 3 Depression Trial Results ↗

February 17, 2026

The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

Via Stocktwits

HUMA Stock Just Shot Up 12% Today – Here’s Everything To Know About The DOD Funding Fueling The Surge ↗

February 09, 2026

The company stated that its product, Symvess, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration.

Via Stocktwits

Why Is ALVO Stock Rising Pre-Market Today? ↗

February 05, 2026

The company reported that the study showed AVT80, its biosimilar candidate to Entyvio, met all primary endpoints.

Via Stocktwits

The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate

February 02, 2026

The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative...

Via MarketMinute

Topics ETFs Government Initial Public Offering

Regeneron’s New Growth Engine Is Starting To Show – But Core Eylea Weakness Weighs On REGN Stock ↗

January 30, 2026

Fourth-quarter revenue increased 3% from a year earlier to $3.88 billion, topping Wall Street expectations of $3.78 billion, according to Fiscal.ai data.

Via Stocktwits

Why Did SER Stock Surge Over 70% In Pre-Market Today? ↗

January 29, 2026

The U.S. Food and Drug Administration cleared its Investigational New Drug application for SER-252, a therapy to treat patients with Parkinson’s disease.

Via Stocktwits

This Wealth Manager Just Dumped Its Entire $3.5 Million Stake in the iShares Biotech ETF ↗

January 27, 2026

The iShares Biotechnology ETF tracks U.S. biotech firms, offering exposure to companies advancing research, development, and innovation.

Via The Motley Fool

Topics Derivatives ETFs Regulatory Compliance

2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗

January 24, 2026

Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps.

Via The Motley Fool

Topics ETFs Intellectual Property World Trade

The Software Surge: How 2024’s $25.7 Billion M&A Explosion in Diagnostics Redefined Healthcare

January 23, 2026

The healthcare landscape underwent a seismic shift in 2024, as the industry’s major players pivoted away from traditional hardware toward high-margin diagnostic platforms and artificial intelligence...

Via MarketMinute

Topics Artificial Intelligence Economy

The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market

January 22, 2026

The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year...

Via MarketMinute

Topics Artificial Intelligence ETFs Initial Public Offering

Why NVAX Stock Is Popping Pre-Market – And What Does Pfizer Have To Do With It? ↗

January 20, 2026

The company signed a licensing agreement with Pfizer, granting it non-exclusive rights to use Matrix-M adjuvant in up to two disease areas.

Via Stocktwits

Why This Fund Cashed Out of a $3.6 Million Biotech ETF Bet ↗

December 26, 2025

After a strong biotech rebound, one fund quietly walked away from sector beta, and the timing says more than the trade itself.

Via The Motley Fool

Topics ETFs Regulatory Compliance

< Previous 1 2 3 4 5 6 7 8 9

...

28 29 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.